Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Phase III, Multi-center, Open-label, Randomized Study to Assess the Efficacy and Safety of Org 37462 Treatment in Chinese Women Undergoing Controlled Ovarian Stimulation for IVF or ICSI, Using a Long Protocol of Triptorelin as a Reference Treatment.
Brief Summary: The primary purpose of this study is to assess that ganirelix is safe and well-tolerated in Chinese women and that a controlled ovarian stimulation (COS) protocol combining recombinant follicle stimulating hormone (recFSH) with ganirelix is efficient in Chinese women undergoing COS for in vitro fertilization (IVF) or intra cytoplasmatic sperm injection (ICSI).


Options:
A: Inclusion Criteria:

* females of infertile couples for whom COS and IVF or ICSI is indicated
* body mass index between 18 and 29 kg/m2
* willing and able to give written informed consent.

Exclusion Criteria:

* More than three previous COS cycles for assisted reproduction since last established ongoing pregnancy (if applicable)
* History of no or low ovarian response to FSH/human menopausal gonadotropin (hMG) treatment
* Less than 2 ovaries or any other ovarian abnormality including endometrioma
* Presence of unilateral or bilateral hydrosalpinx
* Any ovarian and/or abdominal abnormality that would interfere with adequate ultrasound investigation of at least one ovary
* History of or current polycystic ovary syndrome (PCOS)
* History of/or current endocrine abnormality
* Any clinically relevant hormone value outside the reference range during the early follicular phase
* Any clinically significant abnormal laboratory value
* Hypertension or currently treated hypertension
* Recent history of current epilepsy, diabetes, cardiovascular, gastro-intestinal, hepatic, renal, pulmonary disease
* Alcohol or drug abuse, or history thereof
* Current serious allergic symptoms
* Abnormal cervical smear
* Known hypersensitivity to gonadotropin releasing hormone (GnRH) or its analogs;
* Contra-indications for the use of gonadotropins
* Use of hormonal preparations within 1 month prior to the date of signing consent;
* Administration of any investigational product within 3 months prior to screening.
B: Inclusion Criteria:

* Puregon® (recFSH)/Orgalutran® group:

  * Women with a pregnancy of \>= 16 weeks after Puregon® /Orgalutran® treatment for IVF or ICSI and ET of fresh embryos. Treatment is defined as having had at least one injection of Orgalutran®.
  * Women between 18 and 39 years of age (inclusive) at the day of hCG.
  * Women who are able and willing to sign informed consent.

Controls

* Infants (gestational age \>=16 weeks) of women pregnant after COH using a GnRH agonist in a long protocol for IVF or ICSI and ET of fresh embryos.
* Infants of women between 18 and 39 years of age (inclusive) at the day of hCG.
* The most recent 1000 infants delivered prior to January 1, 2001.

Exclusion Criteria:

* None
C: Inclusion Criteria:

* women of good physical and mental health
* under 37 years old, with regular menstrual cycles of 25-35 days
* normal basal FSH and LH levels
* BMI less than 30 kg/m2
* presence of both ovaries and intact uterus
* absence of polycystic ovaries
* endometriosis, or gynaecological / medical disorders and a negative result in a screening for sexually transmitted diseases
* all patients signed a written informed consent form
* no patient had received any hormone therapy for at least 60 days preceding the study.
D: Inclusion Criteria:

* age \< 39
* follicle-stimulating hormone (FSH) \< 12
* gonadotropin dose 100-300IU

Exclusion Criteria:

* endometriosis
* known endocrine disorder
* blood analyzed in another laboratory

Answer: A